- Companies
- Doctolib
Doctolib Revenue, Valuation, Funding & Investors
Doctolib is valued at $6.4B as of March 2022, a 16.0x revenue multiple. Doctolib revenue was $400M, as disclosed with its latest round.
Last Doctolib valuation
$6.4B
Series F · Mar 2022
Last Doctolib funding round
$554M
Series F · Mar 2022
Doctolib revenue
$400M
Series F · Mar 2022
Key investors in Doctolib
Bpifrance
Kerala Ventures
Accel
Eurazeo
Pierre Kosciusko-Morizet
Bertrand Jelensperger
About Doctolib
Doctolib is a Paris-headquartered online booking platform serving 80,000+ practitioners across France, Germany, Italy, and expanding regions. Patients book appointments 24/7 with GPs, dentists, and therapists via app or web. The software manages agendas, teleconsultations, and prescriptions, integrating with French and German health records. Founded in 2013, it handles 100 million annual appointments.
Founded
2013
HQ
Website
Status
Privately held
Customer focus
B2B & B2C
Revenue model
Commission, Subscription
Revenue
$400M (Mar 2022)
Valuation
$6.4B (Mar 2022)
Doctolib Valuation
Doctolib is currently valued at $6.4B, based on its Series F in March 2022.
The $554M round was led by Eurazeo, with participation from General Atlantic and Bpifrance.
Doctolib's valuation has grown 5.7x from $1.1B at its Series E in March 2019 to $6.4B in March 2022, across 2 priced rounds.
Doctolib valuation by funding round
Revenue multiple| Date | Stage | Valuation | Revenue Multiple |
|---|---|---|---|
| Mar 2022 | Series F | $6.4B | 16.0x |
| Mar 2019 | Series E | $1.1B | - |
Doctolib Revenue
Doctolib's latest recorded revenue is $400M, as of its Series F in March 2022. At a $6.4B valuation, that implies a 16.0x revenue multiple.
Doctolib revenue by funding round
| Date | Revenue * | Valuation | Revenue Multiple | Stage |
|---|---|---|---|---|
| Mar 2022 | $400M | $6.4B | 16.0x | Series F |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
Doctolib Funding History
Doctolib has raised a total of $818M across 7 funding rounds, plus 1 secondary share sale.
Doctolib's first fundraising round was a $1M seed round in February 2014. The most recent completed round was a $554M Series F in March 2022.
Doctolib funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Apr 2026 | Secondary | Invus; ATHOS KG; Generation Investment Management; Salica Investments; A.P. Moller Holding | $348M | - | - |
| Mar 2022 | Series F | Eurazeo (lead); General Atlantic; Bpifrance | $554M | $6.4B | Doctolib is a French healthcare technology platform that provides an online booking system for patient doctor appointments alongside a comprehensive suite of tools for healthcare practitioners, including patient management systems, teleconsultation services, and clinical note-taking capabilities. In March 2022, the company closed a Series F funding round at a post-money valuation of $6.4 billion, securing $549 million in combined equity and debt financing from investors including Eurazeo, Bpifrance, and General Atlantic. At the time of the 2022 round, the company was serving nearly 300,000 healthcare workers across Europe and was working with 250 public hospitals, though specific revenue figures for that period were not publicly disclosed. Doctolib subsequently achieved significant financial milestones, reaching €348 million in annual recurring revenue (ARR) by 2024, representing 22.5% year-over-year growth, with 99% of revenue derived from subscriptions paid by healthcare practitioners. The company has prioritized reinvestment in research and development, particularly in clinical artificial intelligence applications, spending €115 million on R&D in 2024 while working toward profitability, and as of early 2025 was positioned as France's most highly-valued VC-backed company alongside Mistral AI at €5.8 billion valuation. |
| Mar 2019 | Series E | General Atlantic (lead); Kernel Investissements; Bpifrance; Eurazeo; Accel | $168M | $1.1B | Doctolib is a French healthtech company founded in 2013 that provides an online platform for booking doctor appointments, electronic health records (EHR), telemedicine, and management tools for healthcare practitioners across Europe, including France, Germany, Italy, Spain, Belgium, Netherlands, Portugal, Switzerland, Austria, and Luxembourg. It monetizes primarily through SaaS subscriptions paid by doctors, such as €139/month for patient booking (Doctolib Patient), €1.6K/year for EHR (Doctolib Médecin), and additional fees for telemedicine and card readers, with patients using the service for free. The company reached unicorn status with a €150 million Series D round in March 2019 led by General Atlantic, involving investors like Accel, Bpifrance, Eurazeo, and Kernel Investissements, marking its first major valuation milestone after six years. In March 2022, it raised $549 million in equity and debt from General Atlantic and Eurazeo at a $6.4 billion valuation. Doctolib has shown steady growth, reporting €348 million ARR in 2024 (up 22.5% from 2023), with 99% from practitioner subscriptions, France at 80% (~€278M), Germany ~20%, and accelerated new ARR growth of 42% in H2 2024. It serves 80 million patients and 400,000 healthcare professionals but remains pre-profitability, with 2024 losses at €53.8 million (down 38% from €87.1M in 2023) due to heavy R&D investment (€115M in 2024, ~one-third of revenue on AI and innovation), planning profitability in 2025. Competitively, Doctolib holds a dominant position in France (over 50-90% of online appointments, 40% of teleconsultations) but faces peers like Cegedim (€654.5M revenue 2024) and CompuGroup Medical (€1.15B revenue 2024). It recently received a €4.665M fine from French authorities for anti-competitive clauses in practitioner contracts until 2023, which it is appealing, following a 2019 complaint. The company has disclosed financials publicly for the first time ahead of a potential IPO, emphasizing transparency and long-term strategy. |
| Nov 2017 | Series D | Eurazeo (lead); Bpifrance | $42M | - | Doctolib is a European healthtech company providing an all-in-one platform for online medical appointment booking, telemedicine, and related services for healthcare professionals and patients, initially targeting France and expanding to Germany and Italy. It raised a €35 million Series C round from Eurazeo and BPI (Bpifrance) in November 2017, following a €18 million Series B from Accel in October 2015. The company partnered with AP-HP, a major public hospital group in Paris, in May 2017 to expand its reach. Doctolib positioned itself in a large addressable market, starting with an estimated €273 million ARR opportunity in France based on 228,000 doctors at €99 per month pricing for its Doctolib Patient product, later expanding the TAM to €4.5 billion through geographic growth, price increases to €129 per month, and new products like Doctolib Médecin, Doctolib Reader, and Doctolib Telemedicine. later metrics include €348 million ARR and -€53.8 million adjusted EBITDA in 2024, with Germany contributing 17% of ARR by then. The platform grew significantly post-2017, serving 25 million patients and 100,000 healthcare professionals in Germany by 2024 with 50-60% annual growth rates, and merged with French competitor MonDocteur in 2018. Doctolib faced regulatory scrutiny, including a €4.665 million fine from the French Competition Authority in November 2025 for abusing dominance in online booking and teleconsultation markets. |
| Jan 2017 | Series C | Bpifrance (lead); Kerala Ventures; Ludwig Klitzsch; Pierre Kosciusko-Morizet; Accel; Nicolas Brusson | $28M | - | Doctolib is a French healthcare platform offering online appointment booking, management software, video consultations, and digital prescriptions, operating primarily in France and Germany as of 2017. The company was founded in 2013 and had expanded to Germany by early 2017. In January 2017, Doctolib announced a funding round led by Bpifrance, with participation from investors including Accel, Kerala Ventures, Ludwig Klitzsch, Nicolas Brusson, and Pierre Kosciusko-Morizet. A follow-on round in November 2017 raised $42 million (€35 million) from Eurazeo and Bpifrance, bringing total 2017 funding to approximately $72.7 million (€61 million). At the time of the 2017 rounds, Doctolib had significant traction with 30,000 health professionals using the platform across France and Germany, managing 1.5 million bookings in Germany alone, and attracting 12 million monthly visitors. The company employed around 380 people and charged practitioners €109 per month in France and €129 in Germany for its SaaS service, replacing traditional booking systems. Plans included hiring 100 employees each in France and Germany to solidify leadership in both markets. Later rounds included a March 2019 Series E led by General Atlantic at over $1.1 billion valuation and a March 2022 round reaching $6.4 billion. Doctolib continued growth, partnering with hospitals and expanding services. |
| Oct 2015 | Series B | Accel (lead); Kerala Ventures; Bertrand Jelensperger; Pierre Kosciusko-Morizet; Nicolas Brusson | $20M | - | Doctolib, a Paris-based startup founded in 2013, raised an €18 million ($20 million) Series B funding round on October 13, 2015, led by Accel Partners with participation from angels including Bertrand Jelensperger (LaFourchette co-founder), Pierre Kosciusko-Morizet (PriceMinister founder), and Nicolas Brusson (BlaBlaCar co-founder). This brought total funding to €23 million after a prior €5 million round. The company provides a SaaS platform for medical appointment booking, management, and patient reminders, reducing no-shows by up to 75% and helping doctors acquire up to 20 new patients monthly. By late 2015, it had signed up over 5,000 doctors and 100 clinics across 80 specialisms in France, serving two million patients monthly, with 15 regional offices. The subscription-based service targets individual physicians to large hospitals, enabling real-time availability checks, online bookings, and compliance with French health data laws. Doctolib positioned itself in a market of 8 billion annual European medical appointments, aiming to expand internationally from its French base to become Europe's top doctor booking platform. Funds were allocated to growth in France and entry into new European countries, competing with DocPlanner, Zesty, and KelDoc. Later rounds included a €26 million raise in 2017 with Accel and Bpifrance (total ~€50 million), a €150 million Series E in 2019 at over €1 billion valuation led by General Atlantic, and further growth to $6.4 billion by 2022. |
| Nov 2014 | Series A | Kerala Ventures (lead); Bertrand Jelensperger; Pierre Kosciusko-Morizet | $5M | - | Doctolib raised $4.9 million in its Series A funding round in November 2014 from Bpifrance, Eurazeo, and Kerala Ventures. This followed a €1 million seed round in February 2014 from Kerala Ventures and Bertrand Jelensperger. The round amount is listed as $4,989,653 or €4 million in investor records. Kerala Ventures acted as a cofounding investor since 2013. Doctolib, founded in 2013, provides an online booking platform connecting doctors and patients across Europe. By late 2014, it had gained traction with 1.5K healthcare professionals and 15 hospitals. The company expanded through subsequent rounds, including a Series B of $20 million in October 2015. |
| Feb 2014 | Seed | Kerala Ventures (lead); Olivier Occelli; Antoine Freysz; Bertrand Jelensperger | $1M | - | - |
Who has invested in Doctolib?
17 investors have backed Doctolib across its funding rounds, including Bpifrance, Kerala Ventures, Accel, Eurazeo, Pierre Kosciusko-Morizet and Bertrand Jelensperger.
Lead investors include Eurazeo, General Atlantic, Bpifrance, Accel and Kerala Ventures.
Doctolib Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 4 | Lead | Feb 2014 | ||
| 4 | Lead | Jan 2017 | ||
| 3 | Participant | Feb 2014 | ||
| 3 | Lead | Nov 2017 | ||
| 3 | Participant | Nov 2014 | ||
| 3 | Lead | Oct 2015 | ||
| 2 | Lead | Mar 2019 | ||
| 2 | Participant | Oct 2015 | ||
| 1 | Participant | Feb 2014 | ||
| 1 | Participant | Feb 2014 | ||
| 1 | Participant | Apr 2026 | ||
| 1 | Participant | Jan 2017 | ||
| 1 | Participant | Mar 2019 | ||
This data is available for Pro users. Sign up to see all 17 Doctolib investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Doctolib
Doctolib has acquired 7 companies to date.
Last acquisition by Doctolib was on May 4th 2026. Doctolib acquired Medicus Health for undisclosed valuation.
Latest Acquisitions by Doctolib
| Description | Medicus Health is a patient record system for general practitioners delivering primary care. The platform addresses clinician and patient requirements through its design. | Typeless is a Swiss platform developing digital tools to streamline information exchange for healthcare carers and patients. Based in Zurich, it provides secure messaging, task assignment, and documentation systems tailored for home care services across Europe. Typeless emphasizes data privacy under EU regulations, supporting multilingual interfaces for nursing teams managing chronic care and elderly support. | Aaron.ai is a Berlin-headquartered SaaS provider of conversational AI phone assistants for doctors, automating administrative tasks like appointment scheduling and patient triage. The platform supports German-speaking healthcare providers, including partnerships with the Federal Ministry of Health and National Medical Association for pandemic response efforts. | Siilo is an Amsterdam-headquartered secure messaging platform for healthcare professionals across Europe. Founded in 2016, it offers encrypted chat, video calls, and file sharing compliant with GDPR and HIPAA standards. The app streamlines clinical workflows for multidisciplinary teams in hospitals and clinics, with adoption in the Netherlands, Belgium, and the United Kingdom. | |
| HQ Country | |||||
| HQ City | London | Lausanne | - | Amsterdam | |
| Deal Date | 4 May 2026 | 21 Jun 2024 | 22 May 2024 | 2 Mar 2023 | |
| Valuation | undisclosed | undisclosed | $43M | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Doctolib acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Doctolib Competitors
Doctolib competitors include listed companies like B-Soft Co. and Phreesia, and private ones like Commure, Cityblock Health, Abridge and Grow Therapy.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $200M | - | $7B | 35.0x | ||
| Private | - | - | $5.7B | - | ||
| Private | $117M | - | $5.3B | 45.3x | ||
| Private | $1B | - | $3B | - | ||
| Publicly listed | $157M | ($37M) | $777M | 4.9x | ||
| Publicly listed | $481M | $27M | $623M | 1.2x |
Doctolib Public Comps
Doctolib is still privately-owned, but its public comps include Hims, Duolingo, M3 Inc., Waystar, Doximity, Kunlun, CCC Intelligent Solutions, Life360, Glaukos and Match Group.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.3B | $178M | 3.1x | 2.4x | 40.6x | 24.0x | |||
| $1B | $152M | 5.2x | 4.7x | 35.7x | 17.1x | |||
| $2.2B | $470M | 3.0x | 2.9x | 14.6x | 11.4x | |||
| $1.1B | $390M | 5.6x | 5.0x | 15.9x | 12.0x | |||
| $645M | $229M | 6.2x | 6.0x | 17.4x | 11.7x | |||
| $1.2B | ($230M) | 6.8x | 5.7x | (36.4x) | (112.7x) | |||
| $1.1B | $238M | 4.8x | 4.5x | 21.4x | 10.8x | |||
| $489M | $32M | 6.3x | 4.9x | 95.3x | 25.1x | |||
This data is available for Pro users. Sign up to see all Doctolib competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Doctolib
| When was Doctolib founded? | Doctolib was founded in 2013. |
| Where is Doctolib headquartered? | Doctolib is headquartered in Paris, France. |
| Is Doctolib publicly listed? | No, Doctolib is a private, VC-backed company. |
| What is Doctolib's valuation? | Doctolib was last valued at $6.4B in its Series F in March 2022. |
| How much funding has Doctolib raised? | Doctolib has raised $818M across 7 funding rounds. |
| What was Doctolib's last funding round? | Doctolib's last funding round was a $554M Series F in March 2022, led by Eurazeo. |
| Who are Doctolib's investors? | Doctolib's investors include Kerala Ventures, Bpifrance, Bertrand Jelensperger, Eurazeo, Pierre Kosciusko-Morizet, Accel, General Atlantic, Nicolas Brusson, Olivier Occelli, Antoine Freysz and 7 others. |
| What is Doctolib's revenue? | Doctolib's latest recorded revenue is $400M (March 2022). |
| What is Doctolib's revenue multiple? | Doctolib's latest valuation implies a 16.0x revenue multiple ($6.4B valuation on $400M of revenue). |
| Which companies are comparable to Doctolib? | Companies comparable to Doctolib include Commure, Cityblock Health, Abridge, Grow Therapy, B-Soft Co. and Phreesia. |
| How many companies has Doctolib acquired? | Doctolib has acquired 7 companies, including Medicus Health, Typeless, Aaron.ai, Siilo and Tanker. |
| What was the largest acquisition by Doctolib? | The $70M acquisition of Mondocteur.fr in July 2018 is the largest acquisition Doctolib has made to date. |
See companies similar to Doctolib
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




